BRCA1 and ovarian carcinoma: Patients cited acquiring knowledge for their children’s benefit as their main motivation for participating in genetic testing; however, as connections between therapy success and specific pathogenic variants are identified, such as the potential for poly ADP ribose polymerase inhibitor (PARPi) treatment for ovarian cancer in patients who carry a germline BRCA1/2 pathogenic variant, these motivations may shift [20].